10x Genomics (TXG) Q2 2026 earnings review
Core Growth Stabilizes While Atera Freezes Capital Equipment
Headline numbers look optically messy due to a massive prior-year litigation settlement, but 10x Genomics is demonstrating fundamental stability. Excluding settlements, Q2 revenue grew 3% to $149.4 million, driven by a resilient consumables business. The defining narrative is the upcoming Atera platform: while management touts 'extraordinary' order flow, the anticipation has completely frozen near-term capital equipment purchases, sending instrument revenue down a staggering 47% YoY. Despite this deep 'air pocket' in hardware, disciplined operating expenses and rock-solid consumables demand gave management the confidence to raise full-year guidance to $610-$630 million.
🐂 Bull Case
Total consumables revenue grew 7% YoY to $130.7M. Single Cell consumables stabilized with 3% growth, while Spatial consumables surged 16% YoY, proving customers are highly engaged with existing platforms.
Raising the full-year revenue guide to a midpoint of $620M (2-5% core growth) indicates management sees a firm floor in the business and expects a strong initial Atera shipment ramp in Q4.
🐻 Bear Case
The Atera Osborne effect is severe. Total instrument sales plummeted 47% YoY to $7.6M. Until Atera ships in volume, hardware revenue is essentially dead weight.
Q2 posted an exceptional 74% gross margin. However, management has confirmed Atera carries lower margins than the standard portfolio, meaning profitability will decelerate as the new hardware ramps.
⚖️ Verdict: ⚪
Neutral. The underlying consumables business is remarkably stable and the guidance raise is a strong positive signal. However, the sheer magnitude of the instrument revenue collapse limits near-term upside until Atera proves it can ship at scale.
Key Themes
Proteintech Acquisition Expands Multiomics Capability
10x acquired Proteintech Genomics to integrate advanced protein detection into its single cell and spatial platforms. This is a critical technological driver that directly answers competitor capabilities (like NanoString/Bruker) and unlocks simultaneous RNA and protein analysis, accelerating adoption in translational research.
Atera Excitement Validates Platform Leap
Management reported an 'extraordinary' customer response and strong early order flow for Atera, its next-generation platform. Atera removes long-standing bottlenecks by enabling whole-transcriptome analysis with single-cell sensitivity at massive scale, structurally positioning 10x to capture the ballooning demand for AI-driven biological data generation.
Consumables Resilience Anchors the Business
While hardware sales vanish, recurring revenue is stepping up. Total consumables reached $130.7M (87% of core revenue), accelerating slightly from prior quarters. Spatial consumables grew 16% YoY to $42.3M, proving that utilization on the existing installed base remains highly robust.
Atera Cannibalization Freezes Current Instruments
Management previously claimed Atera would 'expand the market', but current data contradicts the narrative of a smooth transition. The anticipation of Atera has caused a brutal and immediate freeze in legacy purchasing. Spatial instrument sales fell 48% YoY ($4.5M vs $8.7M) and Single Cell instruments fell 46% YoY ($3.0M vs $5.7M). Reversing this severe deceleration is entirely dependent on Atera execution in Q4.
Macro CapEx Constraints Persist
Beyond the product transition, the structural freeze on academic and biopharma capital expenditures remains a heavy anchor. Elevated scrutiny on large equipment purchases continues to delay project timelines and stretch out sales cycles, a trend that could threaten the velocity of the Atera rollout if budgets remain tight.
Peak Gross Margins Face H2 Dilution
Gross margin expanded to an excellent 74% in Q2, aided by lower manufacturing costs and $2.6M in tariff refunds. However, this is likely a cyclical peak. Management previously confirmed Atera hardware operates at lower margins than the standard portfolio. As Atera unit mix increases in H2, gross margins are mathematically guaranteed to decelerate.
Other KPIs
Headline operating expenses surged 39%, but this is purely an accounting artifact. The prior year included a massive $40.7M litigation settlement gain, compared to just $3.4M this quarter. Excluding these non-recurring settlement impacts, operating expenses were effectively flat YoY. Management is demonstrating excellent cost control through a difficult product transition.
Liquidity continues to strengthen. The cash pile expanded from $540M in Q1 and $523M at the end of FY25. This pristine balance sheet allows 10x to fund the Atera launch and opportunistic tuck-in acquisitions (like Proteintech) without tapping debt or equity markets.
Guidance
Accelerating. 10x raised the floor and ceiling of its full-year guidance (previously $600M-$625M). Excluding non-recurring litigation revenue from both years, this implies 2% to 5% growth over FY25. This raise is highly encouraging, indicating that despite the Q2 instrument freeze, management has strong visibility into H2 consumables pull-through and Atera initial shipments.
Key Questions
Atera Production Ramp
Given the 47% drop in legacy instrument sales, there is immense pressure on Atera to deliver in Q4. What is the current production capacity for Atera hardware through the end of the year, and are there any supply chain bottlenecks limiting the initial launch?
Proteintech Integration Timeline
With the Proteintech Genomics acquisition closing, how quickly can customers expect integrated protein detection kits for Xenium, and will this capability command a pricing premium over standalone RNA consumables?
Margin Dilution Severity
Gross margins hit 74% this quarter but will face pressure from lower-margin Atera placements. What is the normalized gross margin profile we should model for 2027 once Atera becomes the dominant hardware standard?